246 related articles for article (PubMed ID: 34798201)
21. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
Reich K; Foley P; Han C; McElligott S; Muser E; Li N; Armstrong AW
J Dermatolog Treat; 2020 Sep; 31(6):617-623. PubMed ID: 31305186
[No Abstract] [Full Text] [Related]
22. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
Jo SJ; Huang YH; Tsai TF; Kim BS; Reich K; Saadoun C; Chang CL; Yang YW; Youn SW
J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
26. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
Teeple A; Muser E
J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
[No Abstract] [Full Text] [Related]
27. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Nakamura M; Lee K; Jeon C; Sekhon S; Afifi L; Yan D; Lee K; Bhutani T
Dermatol Ther (Heidelb); 2017 Sep; 7(3):281-292. PubMed ID: 28639011
[TBL] [Abstract][Full Text] [Related]
28. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
Puig L
Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
30. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
31. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
Rahman P; Ritchlin CT; Helliwell PS; Boehncke WH; Mease PJ; Gottlieb AB; Kafka S; Kollmeier AP; Hsia EC; Xu XL; Shawi M; Sheng S; Agarwal P; Zhou B; Ramachandran P; Zhuang Y; McInnes IB
J Rheumatol; 2021 Dec; 48(12):1815-1823. PubMed ID: 33934076
[TBL] [Abstract][Full Text] [Related]
32. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
33. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
34. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A; Thaçi D; Papp KA; Ho V; Ghoreschi K; Kim BS; Miller M; Shen YK; You Y; Chan D; Yu J; Yang YW; Lebwohl MG; Gottlieb AB; Crowley J; Foley P
Br J Dermatol; 2023 Jul; 189(1):132-134. PubMed ID: 36944555
[No Abstract] [Full Text] [Related]
35. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
Li N; Teeple A; Muser E; You Y; Song M; Armstrong AW
J Dermatolog Treat; 2022 Feb; 33(1):278-283. PubMed ID: 32233940
[TBL] [Abstract][Full Text] [Related]
36. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
Yang J; Wang Z; Zhang X
J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
[TBL] [Abstract][Full Text] [Related]
37. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A; Costanzo A; Fargnoli MC; Malagoli P; Piaserico S; Amerio P; Argenziano G; Balato N; Bardazzi F; Bianchi L; Carrera CG; Conti A; Dapavo P; De Simone C; Loconsole F; Lo Schiavo A; Malara G; Musumeci ML; Parodi A; Peris K; Prignano F; Rongioletti F; Talamonti M; Potenza C
Eur J Dermatol; 2021 Feb; 31(1):3-16. PubMed ID: 33648915
[TBL] [Abstract][Full Text] [Related]
38. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
Ferris LK; Ott E; Jiang J; Hong HC; Li S; Han C; Baran W
J Dermatolog Treat; 2020 Mar; 31(2):152-159. PubMed ID: 30887876
[No Abstract] [Full Text] [Related]
40. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
